Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 10/20 | 0.62 |
| ▸ | DRD3 | P35462 | 7/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | DRD5 | P21918 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8168957 | 1.00 | HTT (0.70) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL7050984 | 0.98 | HTT (0.72) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL6555514 | 0.82 | HTT (1.00) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL7654044 | 0.82 | HTT (0.68) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL28588828 | 0.82 | HTT (0.68) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL14662685 | 0.82 | HTT (0.68) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL9279775 | 0.81 | HRH3 (0.54) | HTTSMN1; SMN2ALDH1A1SIGMAR1GAA | |
| SCHEMBL11377879 | 0.81 | HTT (0.66) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL2026093 | 0.81 | HTT (0.66) | HTTDRD4DRD3DRD2DRD5 | |
| SCHEMBL1037058 | 0.81 | HTT (0.66) | HTTDRD4DRD3DRD2DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| CN-101031543-A | Process for preparing aromatic thiophenyl ketones | CIBA SC HOLDING AG (CH) | 2007-09-05 | — | — | CN | claimed |
| US-4772704-A | ANTIULCER AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-09-20 | — | — | US | claimed |
| EP-2931722-B1 | SUBSTITUTED 1H-PYRROLO [2,3-B]PYRIDINE AND 1H-PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-109563092-A | It can be used as the 2- phenylimidazole of the active inhibitor of mammal tyrosine kinase ROR1 simultaneously [4,5-B] pyridine -7- amine derivative | 坎塞拉有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-107567445-A | It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor | 坎塞拉有限公司 | 2018-01-09 | — | — | CN | disclosed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| CN-101115749-B | Aminopyrimidine compounds and methods of use | AMGEN INC | 2011-06-22 | — | — | CN | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| CN-101031543-A | Process for preparing aromatic thiophenyl ketones | CIBA SC HOLDING AG (CH) | 2007-09-05 | — | — | CN | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| CN-1738801-A | Diarylmethylidene piperidine derivatives, their preparation and their use | ASTRAZENECA AB (SE) | 2006-02-22 | — | — | CN | disclosed |
| CN-1549816-A | N-aroyl cyclic amine derivatives as orexin receptor antagonists | ʷ | 2004-11-24 | — | — | CN | disclosed |
| WO-1999031096-A1 | PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS | SHAMAN PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5610303-A | MONOAMIDE OXIDASE INHIBITORS | UBE INDUSTRIES, LTD. (JP) | 1997-03-11 | — | — | US | disclosed |
| US-4772704-A | ANTIULCER AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | HTT 2363/4885DRD4 4387/4885DRD3 4653/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | HTT 2363/4885DRD4 4387/4885DRD3 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.